GT Biopharma Inc. Common Stock (GTBP) Stock Price

GTBPStock

$7.03−58.77%52W

Market Cap$14.49M

P/E—

PEG Ratio1.05

Div yield—

Beta0.80

GTBP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-37.58%

Price vs S&P 500 (4W)-0.76%

PEG Ratio1.05

VGM Score30.95

Book Value / Share (Quarterly)$2.00

P/TBV (Annual)52.56x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-8.07

Price vs S&P 500 (YTD)-76.11%

Gross Margin (TTM)36.51%

Net Profit Margin (TTM)-26209.52%

EPS (TTM)$-47.51

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-47.51

EPS (Annual)$-173.41

Dividend / Share (Annual)$0.41

ROI (Annual)-101.62%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-26774.13%

Cash / Share (Quarterly)$2.78

ROA (Last FY)-311.01%

EBITD / Share (TTM)$-9.05

ROE (5Y Avg)-569.56%

Operating Margin (TTM)-8623.81%

Cash Flow / Share (Annual)$-12.64

P/B Ratio4.06x

P/B Ratio (Quarterly)6.08x

Net Income / Employee (Annual)$-13,162,000

EV / Revenue (TTM)151.26x

Net Interest Coverage (TTM)-80.82x

ROA (TTM)-313.11%

EPS Incl Extra (Annual)$-173.41

Current Ratio (Annual)3.50x

Quick Ratio (Quarterly)2.51x

3-Month Avg Trading Volume0.05M

52-Week Price Return-58.77%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.24

P/S Ratio (Annual)536.64x

Asset Turnover (Annual)0.50x

52-Week High$28.75

Operating Margin (5Y Avg)-10668.30%

EPS Excl Extra (Annual)$-173.41

26-Week Price Return-27.67%

Quick Ratio (Annual)3.25x

13-Week Price Return-21.01%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.61x

Enterprise Value$9.53M

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-70.58%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)2.71x

Pretax Margin (Annual)-79485.19%

Cash / Share (Annual)$6.67

3-Month Return Std Dev142.89%

Gross Margin (5Y Avg)26.61%

Net Income / Employee (TTM)$-22,083,000

ROE (Last FY)-101.62%

Net Interest Coverage (Annual)-236.49x

EPS Basic Excl Extra (Annual)$-173.41

P/FCF (TTM)1317.20x

Receivables Turnover (TTM)3.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-47.51

Receivables Turnover (Annual)3.05x

ROI (TTM)-443.08%

P/S Ratio (TTM)229.99x

Pretax Margin (5Y Avg)-26782.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.36

Price vs S&P 500 (52W)-74.30%

Year-to-Date Return-64.19%

5-Day Price Return3.38%

EPS Normalized (Annual)$-173.41

ROA (5Y Avg)-233.96%

Net Profit Margin (Annual)-79485.19%

Month-to-Date Return8.66%

Cash Flow / Share (TTM)$-0.27

EBITD / Share (Annual)$-189.25

Operating Margin (Annual)-33062.96%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-352.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-47.51

P/TBV (Quarterly)52.56x

P/B Ratio (Annual)1.44x

Inventory Turnover (TTM)2.71x

Pretax Margin (TTM)-26238.10%

Book Value / Share (Annual)$5.67

Price vs S&P 500 (13W)-23.70%

Beta0.80x

P/FCF (Annual)42.37x

Revenue / Share (TTM)$0.00

ROE (TTM)-443.08%

52-Week Low$4.91

vGradeF

mGradeC

vgmGradeD

GTBP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$2.00	-$3.00	-50.00%(-$1.00)
Q1 2026	May 15, 2026	-$2.00	-$2.75	-37.50%(-$0.75)
Q4 2025	Mar 2, 2026	-$5.50	-$121.00	-2100.00%(-$115.50)
Q3 2025	Nov 14, 2025	-$9.50	-$20.75	-118.42%(-$11.25)
Q2 2025	Aug 14, 2025	-$0.68	-$0.55	+19.12%(+$0.13)

GTBP Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GTBPGT Biopharma Inc. Common Stock	F	—	C	230.0x	—	36.5%	—	$7.03
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About GT Biopharma Inc. Common Stock

GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology drugs using its proprietary TriKE platform. The platform's therapeutic candidates are designed to treat hematologic malignancies, sarcoma, and solid tumors. The company is advancing these novel therapies toward commercialization in the U.S.